Objective To investigate the characteristic of top-down attentional control of acute stress disorder children.Methods According to SCID-IV-TR,23 acute stress disorder children were chosen as the experinent group and 23 normal children were chosen as the control group.They were asked to perform a visual search task.Results (1) The reaction time of acute stress disorder children((1 253±158)ms) was significantly longer than normal children's((1 194± 146) ms) (P＜0.05).(2) The reaction time of valid condition((1 172± 144) ms)was significantly shorter than neutral condition ((1 229± 156) ms) and invalid condition ((1 269± 157) ms) (P＜0.05),there was no difference of reaction time between neutral condition((1 229± 156)ms) and invalid condition ((1 269±157)ms) (P＞0.05).(3) The reaction time of simple display condition((1 182±127)ms) was significantlv shorter than complex display condition ((1 264± 177)ms) (P＜0.01).Conclusion The performance of acute stress disorder children on top-down attentional control is less than normal children,the reason is that inhibiting capacity of acute stress disorder children is lower than normal children.It indicates that trauma event have negative influence on children's inhibiting capacity.

Pharmacoeconomic evaluation is the essential supporting information for the inclusion of rare disease drugs into medical insurance in China. The accurate measurement of the health state utility of rare diseas is of practical significance to the development of rare disease pharmacoeconomic evaluation. Based on the review of pharmacoeconomic evaluation requirements for rare diseases in some countries/regions, we systematically retrieved the published studies on the measurement of health state utility for 121 rare diseases in China and other countries and regions. We identified 17 591 papers in the initial review, and later selected 230 after screening. We also made a comprehensive analysis of the quality of literature, evaluation content and use of tools for measuring health state utility in rare diseases in China. Finally, we analyzed the challenges in measurement in terms of population, instruments use, and application of results and made recommendations based on analysis, hoping to provide reference for the development of rare disease health state utility measurement studies in China.

We have analyzed the current status of recognization and qualification of orphan drugs in China and abroad, looking at the aspects of the authority institutions, identification and qualification process, and the number of orphan drugs identified and available in the market. By comparing and analyzing horizontally the differences in orphan drugs identification between representative developed countries vs. some developing countries, we discuss the inadequacy of orphan drugs supervision in China. We introduce the advanced experience from the developed countries and some developing countries to provide suggestions for the identification and management of orphan drugs, hoping to speed up the process of development and market availability of orphan drugs and to maximize patient's accessibility to treatment in China.